CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...